Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

1. Oliai C, Feldman DR, Slotkin E, et al. Clinical safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT). Presented at: 2026 ESMO ...

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...

The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic ...

Matthew Gubens, MD, MS, explains how targeted therapies are moving into earlier-stage non–small cell lung cancer, while ...

The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...

These developments also strengthen the rationale for next-generation sequencing (NGS) in patients with early-stage disease.